Skip to content
Sign in
Artwork for OncoPharm
OncoPharm · April 9 · 15 min

Relacorilant

Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce. Also, a 10-year follow-up study of ibrutinib provides big picture insight on the impact of the BTKi era in CLL. Link: https://doi.org/10.1182/blood.2025029971 Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

0:00-15:13
Play in

transcript

No transcript — this publisher did not publish one.

show notes

Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce.

Also, a 10-year follow-up study of ibrutinib provides big picture insight on the impact of the BTKi era in CLL. Link: https://doi.org/10.1182/blood.2025029971

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

more episodes

All episodes